Jerry Gleich
Chief Scientific Officer (CSO)
NexEos Bio
NexEos Bio develops NDX-3324, a non-invasive imaging agent designed for the diagnosis and management of Eosinophilic Esophagitis (EoE), a chronic condition characterized by eosinophil-driven inflammation. The technology enables precise monitoring of disease progression, improving patient quality of life through targeted treatment strategies.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$22.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Eosinophilic Esophagitis (EoE) diagnosis and management currently rely on invasive endoscopies with biopsies, which are resource-intensive, carry risks, and may not accurately capture the patchy nature of esophageal inflammation. The current standard presents a barrier to frequent monitoring and timely treatment adjustments, impacting patient quality of life.
Solution
NexEos Bio is developing NDX-3324, a non-invasive imaging agent designed to improve the detection, diagnosis, monitoring, and treatment management of EoE. NDX-3324 is administered orally and used in conjunction with SPECT (single-photon emission computed tomography), with or without CT (computed tomography), to visualize and evaluate inflammation in the esophagus. This approach offers a more comprehensive assessment of the entire esophagus compared to traditional biopsies, potentially reducing the time from symptom onset to diagnosis and enabling better ongoing disease monitoring to optimize therapies. By providing a non-invasive alternative, NDX-3324 aims to minimize patient discomfort and the risks associated with repeated endoscopies.
Target Audience
The primary target audience includes gastroenterologists, pediatricians, and other healthcare providers involved in the diagnosis and management of Eosinophilic Esophagitis, as well as patients suffering from EoE.
Features
- Non-invasive oral imaging agent compatible with SPECT and CT imaging modalities.
- Potential for comprehensive assessment of esophageal inflammation, addressing the patchy nature of EoE.
- Aims to reduce the need for invasive endoscopies and biopsies in EoE diagnosis and monitoring.
- Designed for use in detection, diagnosis, and ongoing treatment management of EoE.
- Granted Fast Track designation by the FDA.